Increasing the speed and efficiency of clinical studies is a priority of most clinical operations professionals. However, according to CenterWatch 86% of clinical trials experience delays. One approach to speed up the translation portion of the clinical process is the use of machine translation (MT), a technology that automatically produces translations of text without human intervention. MT output is frequently part of a larger translation workflow that involves humans as post-editors or reviewers.
MultiLingual magazine recently published a white paper authored by leading language technology and MT experts at Welocalize: “Machine Translation: Neural or Neutral?” The paper gives insight into the MT landscape and explores neural machine translation (NMT) considering the notion that NMT should be put into production immediately.
One of the key arguments highlighted in this piece is that the approach should be measured, citing that in the commercial world of MT, neural, statistical and rules-based engines all have a role to play.